Fig. 5. Clinical data with BLU-285 confirm early evidence of activity in patients with diseases driven by KIT and PDGFRA activation loop mutations. Clinical.

Slides:

Advertisements

Similar presentations

A Proposal for BMS (Dasatinib) in GIST Jon Trent, MD, PhD Assistant Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson.

Advertisements

Update on GIST Research

Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.

Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.

RECIST Overview.

Updated Results of a Phase I First-in-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic.

Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.

Copyright © 2011 American Medical Association. All rights reserved.

Figure 2 Response after initial increase in total tumour burden

Fig. 1. TP is highly expressed in myeloma.

Examples of functional imaging biomarkers in two DCA responders

Optimizing Outcomes in the Management of GIST

NSCLC. NSCLC. A, antitumor activity of abemaciclib in 4 KRAS-mutant (NCI-H358, NCI-H2122, NCI-H441, NCI-H460) and 2 KRAS wild-type (WT; NCI-H1650, NCI-H1975)

Fig. 1. IL-6 is associated with resistance to EGFR TKIs and is induced by stress hormones. IL-6 is associated with resistance to EGFR TKIs and is induced.

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets Case Rep Oncol 2016;9:

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

β-ARs signal cooperatively with mutant EGFR and inactivate LKB1

Fig. 1. Anemia in patients with central diabetes insipidus.

Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 3. Frequencies of amino acids at critical PGT121 and contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Fig. 6. N95BA5 biocompatibility beyond intended use frame.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 7. The PD-L1 defect is evident in HSPCs from T1D patients.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells by Angela Colmone, Maria Amorim, Andrea L.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy.

Fig. 1. scRNA-seq applications in cancer medicine.

Fig. 1. MAHALO clinical trial flowchart.

Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.

Fig. 4. BLU-285 demonstrates antitumor activity across multiple KIT-driven in vivo disease models. BLU-285 demonstrates antitumor activity across multiple.

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.

Role of immune and inflammatory cells in lung cancer–associated PH

Fig. 3. The effects of DCA on hemodynamic and functional end points and their association with genetic factors (variants of the SIRT3 and UCP2 genes) that.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.

Fig. 6 Alarmin release and sympathetic stress response synergize in poststroke atheroprogression. Alarmin release and sympathetic stress response synergize.

Fig. 7. Genetic ablation of UCP2 compromised the protective effect of exogenous irisin on lung IR injury. Genetic ablation of UCP2 compromised the protective.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Fig. 1. In vivo fates of patient-derived AML cells defined by mutational profile. In vivo fates of patient-derived AML cells defined by mutational profile.

Fig. 1 CSPG4 is expressed in GBM specimens and GBM-NS and associated with more aggressive disease. CSPG4 is expressed in GBM specimens and GBM-NS and associated.

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Evaluation of clinical responses after infusion of CART19 cells

Fig F-FGln shows uptake in human gliomas undergoing progression.

Fig. 3 CSF1 is expressed in human melanoma.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

A precision therapy against cancers driven by KIT/PDGFRA mutations

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.

Representative CT and PET/CT images of three patients with NSCLCs

Evaluation of clinical responses after infusion of CART19 cells

Understanding the Expanding Armamentarium for GIST

Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

Individual treatment outcomes of 20 patients treated with afatinib and 12 patients treated with afatinib and trastuzumab. Individual treatment outcomes.

Representative patient responses to ulixertinib.

Fig. 2 Increasing KLF17, CDH1, and LASS2 expression reduced malignant progression and promoted apoptosis of tumor cells. Increasing KLF17, CDH1, and LASS2.

Serial CT scan images from patient with a partial response.

by Christian Grommes, Sarah S. Tang, Julia Wolfe, Thomas J

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Presentation transcript:

Fig. 5. Clinical data with BLU-285 confirm early evidence of activity in patients with diseases driven by KIT and PDGFRA activation loop mutations. Clinical data with BLU-285 confirm early evidence of activity in patients with diseases driven by KIT and PDGFRA activation loop mutations. (A) BLU-285 [30 mg per os (PO), QD] induces rapid radiographic clinical response per RECIST1.1 (31% tumor reduction at week 8) and decline in PDGFRA D842V ctDNA in a patient with PDGFRA D842V–mutant GIST that progressed on previous imatinib, dasatinib, and crenolanib therapy. The images show CT scans with tumor circled in yellow. The graph shows tumor burden as measured by the sum of the longest dimension for the target lesions (per RECIST1.1) and mutant allele frequency (MAF). (B) Radiographic clinical response per RECIST1.1 with BLU-285 (60 mg PO, QD) in a patient with primary KIT D820Y–mutant GIST that had previously progressed on imatinib, sunitinib, and regorafenib. The images show CT scans with a pelvic tumor mass highlighted within yellow circles that demonstrated a 28% tumor reduction at day 1 of cycle 5. A partial response of 32% tumor reduction was confirmed by central radiographic review at cycle 15. (C) BLU-285 (30 mg PO, QD) markedly decreased bone marrow mast cell burden in a patient with KIT D816V–driven aggressive SM. At baseline, diffuse bone marrow infiltration with malignant mast cells obliterated normal hematopoiesis (left). After BLU-285 treatment, there was a marked reduction in malignant mast cells and return of normal trilineage hematopoiesis (right). Scale bars, 1000 μm (left) and 200 μm (right). Erica K. Evans et al., Sci Transl Med 2017;9:eaao1690 Published by AAAS